MarkPuderMDPhD
Pediatric (General) Surgery • Boston, MAAssociate Professor of Surgery, Boston Children's Hospital
Dr. Puder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave/Fegan 3
Children's Hospital
Boston, MA 02115Phone+1 617-355-3038
Education & Training
Boston Children’s HospitalFellowship, Pediatric Surgery, 1999 - 2001
Beth Israel Deaconess Medical CenterResidency, Surgery, 1988 - 1998
Harvard UniversityPhD, 1993 - 1997
Yale-New Haven Medical CenterResidency, Pediatrics, 1986 - 1988
Vanderbilt University School of MedicineClass of 1986
Certifications & Licensure
MA State Medical License 1991 - 2025- American Board of Surgery Surgery
- American Board of Surgery Pediatric Surgery
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2013
- Fellow (FACS) American College of Surgeons
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Cholestasis Prevention: Efficacy of IV Fish Oil Start of enrollment: 2007 Jul 01
- Cholestasis Reversal: Efficacy of IV Fish Oil Start of enrollment: 2004 Sep 01
- A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB Start of enrollment: 2018 Nov 21
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsA Medium-Chain Fatty Acid Analogue Prevents Intestinal Failure-Associated Liver Disease in Preterm Yorkshire Piglets.Scott C Fligor, Savas T Tsikis, Thomas I Hirsch, Amy Pan, Kamila Moskowitzova
Gastroenterology. 2023-09-01 - 7 citationsTargeting the lung endothelial niche to promote angiogenesis and regeneration: A review of applications.Savas T Tsikis, Thomas I Hirsch, Scott C Fligor, Mikayla Quigley, Mark Puder
Frontiers in Molecular Biosciences. 2022-01-01 - 3 citationsStructurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.Jordon D Secor, Bennet S Cho, Lumeng J Yu, Amy Pan, Victoria H Ko
Lipids. 2022-07-01
Press Mentions
- Alcresta Therapeutics Announces Preclinical Data Showing ALC-078 Cartridge Use in SBS Model Associated with Reduced Dependence on Parenteral NutritionMarch 16th, 2023
Worth the Fight: Finding Care for Short Bowel SyndromeApril 23rd, 2019
An Evolving Story of Translational Research: A Decade After the Jacobson Promising Investigator AwardDecember 30th, 2017- Join now to see all
Grant Support
- Cholestasis Reversal (Phase Ll): Efficacy Of LV Fish OilFood And Drug Administration2008–2010
- Cholestasis Prevention: Efficacy Of IV Fish OilFood And Drug Administration2008–2009
- Mechanisms Of Hepatic Steatosis PreventionNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2009
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
